Heijink Irene H, Van Oosterhout Antoon J M
Laboratory of Allergology and Pulmonary Diseases and Department of Pathology, University Medical Center Groningen (UMCG), Groningen University, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Curr Opin Pharmacol. 2005 Jun;5(3):227-31. doi: 10.1016/j.coph.2005.04.002.
The type 2 T-helper (Th2) lymphocyte can be regarded as an important target cell for the treatment of allergic asthma as it plays a crucial role in the initiation, progression and persistence of disease. Several strategies to target Th2 cells can be envisioned. Drugs that prevent Th2-cells from migrating into the lung tissue, such as antibodies to the chemokine receptor CCR4 and inhibitors of the adhesion molecule VLA-4, are promising for the treatment of asthma. To inhibit Th2-cell activation, novel asthma drugs that act on Th2-selective transciption factors such as GATA3 are being developed. Although initial strategies aimed to block the action of Th2-derived cytokines, the generation of counter-regulatory Th1 lymphocytes and regulatory T cells is currently being explored.
2型辅助性T（Th2）淋巴细胞可被视为治疗过敏性哮喘的重要靶细胞，因为它在疾病的起始、进展和持续过程中起着关键作用。可以设想几种针对Th2细胞的策略。能够阻止Th2细胞迁移到肺组织的药物，如趋化因子受体CCR4抗体和黏附分子VLA-4抑制剂，有望用于哮喘治疗。为抑制Th2细胞活化，正在研发作用于Th2选择性转录因子（如GATA3）的新型哮喘药物。尽管最初的策略旨在阻断Th2衍生细胞因子的作用，但目前正在探索产生反调节性Th1淋巴细胞和调节性T细胞的方法。
